Plasma Derived Therapy Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Plasma Derived Therapy Market size was valued over USD 16.8 billion in 2022 and will grow momentously at 7.5% CAGR between 2023 and 2032. Increasing prevalence of rare diseases including primary immunodeficiency diseases, idiopathic thrombocytopenic purpura (ITP), von Willebrand disease, and others are one of the major factors contributing to the growth of market across the globe. The higher incidence rate of primary immunodeficiency diseases and von Willebrand disease that can lead to severe health conditions will drive the demand for plasma derived therapy.
According to the report published by the Centres for Disease Control and Prevention in 2021, around 3.2 million people in U.S. suffer from von Willebrand disease. Hence, the availability of effective plasma derived therapy that offers effective solution against these rare diseases will lead to unprecedented growth opportunities to the plasma derived therapy industry in the forthcoming years.
Plasma-derived therapy is a highly effective treatment derived from human plasma that is widely used to treat rare and complex diseases. Plasma-derived therapies aid in the replacement of deficient or missing proteins, allowing people to live healthier and more productive lives. Plasma-derived products primarily consist of coagulation factors, albumin, and immunoglobulins, that are used as life-saving therapeutics to treat variety of genetic and life-threatening diseases worldwide.
| Report Attribute | Details |
|---|---|
| Base Year: | 2022 |
| Plasma Derived Therapy Market size in 2022: | USD 34.6 Billion |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 - 2032 CAGR: | 7.5 |
| 2023 Value Projection: | USD 32,765.0 Million |
| Historical Data for: | 2018 to 2022 |
| No of Pages: | 90 |
| Tables, Charts & Figures: | 156 |
| Segments Covered: | Product, Application, and Region |
| Growth Drivers: |
|
| Pitfalls Challenges: |
|
The incidence of coronavirus infection has affected millions of individuals worldwide that had temporarily impacted the plasma donation globally, also affected the plasma derived therapy market. However, due to unavailability of specific treatment medicine and vaccine against COVID-19, research institutes have focused on plasma-based therapy to identify any role in treating the COVID-19. Further, in March 2020, the Houston Methodist Hospital, U.S., announced use of plasma fractionation for treatment of COVID-19 and became the first hospital in U.S. to offer plasma derived therapy among COVID-19 patients. Therefore, high incidence rate of COVID-19 patients has resulted in increased demand for plasma derived immunoglobulins, thereby driving growth of the overall market.
Based on product, the global market is classified into immunoglobulins, coagulation factors, albumin, and other products. Immunoglobulin market held 48.1% business share in 2022.
Based on application, the plasma derived therapy market is categorized into primary immunodeficiency diseases, haemophilia, idiopathic thrombocytopenic purpura (ITP) and others. Haemophilia segment dominated the global market share and was valued at USD 6.5 billion in 2022.
North America market held over 52.2 % business share in 2022 and is projected to experience remarkable growth during the foreseeable future.
Some of the prominent business players operating in the plasma derived therapy industry include CSL Behring, Takeda Pharmaceutical Company Limited, Biotest AG, Octapharma, BPL, ADMA Biologics, Grifols, SA, Kedrion, Kamada Pharmaceuticals, SK Plasma, Pfizer, among others. These market players are adopting various inorganic growth strategies to gain market share and sustainable competitive advantage.
Market players operating in the plasma derived therapy is as mentioned below:
By Product, 2018 – 2032 (USD Million)
By Application, 2018 – 2032 (USD Million)
The above information is provided for the following regions and countries:
Plasma derived therapy industry from the immunoglobulin segment accounted for 48.1% revenue share in 2022 and is estimated to exhibit steady growth through 2032 attributed to the increasing usage for the treatment of several complex diseases globally.
Few leading plasma derived therapy industry players are CSL Behring, Takeda Pharmaceutical Company Limited, Biotest AG, Octapharma, BPL, ADMA Biologics, Grifols, SA, Kamada Pharmaceuticals, SK Plasma
North America held over 52.2% revenue share of the plasma derived therapy industry in 2022 and is estimated to expand at a robust CAGR through 2032 driven by favorable government initiatives and the growing awareness about plasma-derived therapies among blood donors.
Plasma derived therapy industry size exceeded USD 16.8 billion in 2022 and is set to expand at 7.5% CAGR from 2023-2032 owing to the rising prevalence of rare diseases including primary immunodeficiency diseases, idiopathic thrombocytopenic purpura (ITP), and von Willebrand disease.